

23 Jun 2024 | News

# Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: the outlook for 2025 launches; Merck confident in new pneumococcal vaccine; multiple US setbacks for Japanese firms; Stock Watch on Moderna missteps; and Sun's North America head talks plans and strategy.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 21 June 2024, including: the outlook for 2025 launches; [Merck & Co., Inc.](#) confident in new pneumococcal vaccine; multiple US setbacks for Japanese firms; Stock Watch on [Moderna, Inc.](#) missteps; and [Sun Pharmaceutical Industries Ltd.](#)'s North America head talks plans and strategy.

This and all our other podcasts are available on the *Citeline* channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Cagrisema Leads The Charge For 2025](#)" - Scrip, 19 Jun, 2024.)

(Also see "[Merck's Newly Approved Capvaxive Could Have Edge Over Prevnar 20 In Adults](#)" - Scrip, 18 Jun, 2024.)

(Also see "[US R&D Setbacks For Multiple Japanese Firms](#)" - Scrip, 14 Jun, 2024.)

(Also see "[Stock Watch: Thoroughly Moderna Missteps](#)" - Scrip, 18 Jun, 2024.)

# SCRIP

CITELINE COMMERCIAL

(Also see "[Sun's Gandhi On US Specialty Journey Sans 'Baggage', Deuruxolitinib](#)" - Scrip, 17 Jun, 2024.)

[Click here to explore this interactive content online](#) ✨